Two Sigma Investments LP Purchases 87,969 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Two Sigma Investments LP grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 459.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 107,117 shares of the biopharmaceutical company's stock after acquiring an additional 87,969 shares during the quarter. Two Sigma Investments LP owned 0.08% of Alnylam Pharmaceuticals worth $25,206,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Park Avenue Securities LLC boosted its holdings in Alnylam Pharmaceuticals by 64.8% in the 4th quarter. Park Avenue Securities LLC now owns 1,368 shares of the biopharmaceutical company's stock valued at $322,000 after purchasing an additional 538 shares during the period. Merit Financial Group LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $587,000. Perpetual Ltd boosted its stake in shares of Alnylam Pharmaceuticals by 117.2% in the fourth quarter. Perpetual Ltd now owns 8,931 shares of the biopharmaceutical company's stock valued at $2,102,000 after buying an additional 4,819 shares during the period. Nisa Investment Advisors LLC grew its position in Alnylam Pharmaceuticals by 15.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 13,317 shares of the biopharmaceutical company's stock worth $3,134,000 after buying an additional 1,789 shares in the last quarter. Finally, Traynor Capital Management Inc. increased its stake in Alnylam Pharmaceuticals by 29.0% during the 4th quarter. Traynor Capital Management Inc. now owns 9,350 shares of the biopharmaceutical company's stock worth $2,200,000 after acquiring an additional 2,101 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Scotiabank upped their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price on the stock. Needham & Company LLC restated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $292.58 on Thursday. The firm has a market capitalization of $38.15 billion, a price-to-earnings ratio of -134.83 and a beta of 0.17. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The business's 50-day moving average price is $256.73 and its 200-day moving average price is $254.14. Alnylam Pharmaceuticals, Inc. has a 12 month low of $146.79 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same quarter in the previous year, the company posted ($0.16) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.